Career history of Christophe Quéva
Former positions of Christophe Quéva
| Companies | Position | Start | End |
|---|---|---|---|
| ONCORUS, INC. | Chief Tech/Sci/R&D Officer | 2017-09-30 | 2022-08-31 |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Chief Tech/Sci/R&D Officer | 2015-07-31 | 2017-08-31 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 2011-12-31 | 2015-06-30 |
| AMGEN INC. | Corporate Officer/Principal | 2005-12-31 | 2010-12-31 |
Training of Christophe Quéva
| Université De Lille | Doctorate Degree |
Statistics
International
| United States | 4 |
| Belgium | 2 |
| France | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ONCORUS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
- Stock Market
- Insiders
- Christophe Quéva
- Experience
